Go Pro
→ Why I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead) (From Decentralized Masters) (Ad)tc pixel
NASDAQ:SEPN

Septerna Q1 2025 Earnings Report

Septerna logo
$38.51 +0.76 (+2.01%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$38.88 +0.37 (+0.95%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Septerna EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.38
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

Septerna Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Septerna Announcement Details

Quarter
Q1 2025
Date
5/15/2025
Time
After Market Closes
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Septerna's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Septerna's Q1 2025 Press ReleasePress Release
(8-K)
Septerna's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Septerna Earnings Headlines

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 10 at 4:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/10/3359956/0/en/septerna-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html
Septerna to Participate in Upcoming Investor Conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354043/0/en/septerna-to-participate-in-upcoming-investor-conferences.html
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.tc pixel
September 12 at 1:00 AM  |  Eagle Publishing (Ad)
Septerna names Rajiv Patni as CMO
August 25, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/septerna-names-rajiv-patni-as-cmo/ar-AA2aT5tl
Septerna Appoints Rajiv Patni as Chief Medical Officer
August 25, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/septerna-appoints-rajiv-patni-as-chief-medical-officer?utm_source=marketbeat.com&utm_medium=referral
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350365/0/en/septerna-appoints-industry-veteran-rajiv-patni-m-d-as-chief-medical-officer.html
See More Septerna Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email.

About Septerna

Septerna (NASDAQ:SEPN) is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Orthosteric Ligand Discovery platform to study GPCRs in their native cellular environments and identify small-molecule compounds that can modulate these receptors. Septerna’s research and development efforts are directed toward potential treatments in areas including immunology, inflammation, metabolic disease and other conditions with significant unmet medical needs.

Septerna was founded to advance GPCR-directed drug discovery and became a publicly traded company on the Nasdaq under the symbol SEPN. The company is based in the United States and is focused primarily on advancing its internal discovery and clinical-stage pipeline rather than marketing approved products.

View Septerna Profile
Earnings Tools